Medicus Pharma Ltd. (MDCX)
NASDAQ: MDCX · Real-Time Price · USD
2.410
-0.200 (-7.66%)
At close: Sep 17, 2025, 4:00 PM EDT
2.520
+0.110 (4.57%)
After-hours: Sep 17, 2025, 4:13 PM EDT
Company Description
Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets.
It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin.
The company was formerly known as Interactive Capital Partners Corporation and changed its name to Medicus Pharma Ltd. in September 2023.
Medicus Pharma Ltd. was incorporated in 2008 and is headquartered in Conshohocken, Pennsylvania.
Medicus Pharma Ltd.
Country | United States |
Founded | 2008 |
Industry | Drug Manufacturers - General |
Sector | Healthcare |
CEO | Raza Bokhari |
Contact Details
Address: 300 Conshohocken State Road, Suite 200 Conshohocken, Pennsylvania 19428 United States | |
Phone | (610) 540-7515 |
Website | medicuspharma.com |
Stock Details
Ticker Symbol | MDCX |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001997296 |
ISIN Number | CA58471K2020 |
Employer ID | 98-1778211 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Raza Bokhari M.B.A., M.D., MBA | Chief Executive Officer and Executive Chairman |
James P. Quinlan CPA | Chief Financial Officer |
Andrew Alasdair Smith | Chief Operating Officer |
Anna Baran-Djokovic J.D. | Senior Vice President of Investor Relations |
Viktoriia Slepeniuk | Senior Vice President of Public Relations |
Dr. Faisal Mehmud M.D. | Chief Medical Officer |
Maryann Adesso | Chief of Staff and Corporate Secretary |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Sep 15, 2025 | 424B3 | Prospectus |
Sep 15, 2025 | 424B3 | Prospectus |
Sep 15, 2025 | 253G2 | Acc-no: 0001493152-21-027927 (33 Act) |
Sep 15, 2025 | 424B3 | Prospectus |
Sep 12, 2025 | 8-K | Current Report |
Sep 2, 2025 | 424B3 | Prospectus |
Sep 2, 2025 | 424B3 | Prospectus |
Sep 2, 2025 | 424B3 | Prospectus |
Sep 2, 2025 | 253G2 | Acc-no: 0001493152-21-027927 (33 Act) |
Sep 2, 2025 | 8-K | Current Report |